Orgenesis. has filed a patent for a chimeric antigen receptor (CAR) molecule with a modified hinge domain, enhancing anti-tumor activities while reducing pro-inflammatory cytokine release. The isolated molecule includes specific amino acid sequences for improved therapeutic outcomes. GlobalData’s report on Orgenesis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Orgenesis, NSAID cancer drugs was a key innovation area identified from patents. Orgenesis's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Modified chimeric antigen receptor (car) molecule with enhanced anti-tumor activity
The patent application (Publication Number: US20230381230A1) describes an isolated chimeric antigen receptor (CAR) molecule with specific components, including an antigen binding domain, a hinge domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain. The hinge domain in this CAR molecule is defined by a specific amino acid sequence (SEQ ID NO:1) and is encoded by a corresponding nucleotide sequence (SEQ ID NO:2). The antigen binding domain can be a single chain antibody or fragment that binds to various target antigens such as CD19, CD20, CD22, and others from a specified group.
Furthermore, the patent application details the specific amino acid sequences of the antigen binding domain when binding to CD19, including complementary determining regions for both light and heavy chains. The transmembrane domain and costimulatory domain of the CAR molecule are also specified, with options for different proteins to be used in these domains. Additionally, the intracellular signaling domain is defined by specific proteins or functional fragments. The application also covers nucleic acid constructs encoding the CAR molecule, expression vectors containing these constructs, cells expressing the CAR molecule, particularly immune cells like T cells, and compositions comprising these cells along with a pharmaceutically acceptable carrier.
To know more about GlobalData’s detailed insights on Orgenesis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
